Purpose To update the ASCO guideline for antiemetics in oncology. Methods ASCO
convened an Expert Panel and conducted a systematic review of the medical literature for …

Chronic stress is well-known to cause physiological distress that leads to body balance
perturbations by altering signaling pathways in the neuroendocrine and sympathetic …

Despite the considerable progress achieved in the last 30 years, vomiting and, especially,
nausea, continue to be two of the most distressing side-effects of cancer chemotherapy. In …

Nausea and vomiting are still considered to be two of the most troublesome adverse events
(AEs) for patients treated with antineoplastic therapy. To optimise the utility of available …

Background About 70% to 80% of adults with cancer experience chemotherapy‐induced
nausea and vomiting (CINV). CINV remains one of the most distressing symptoms …

Background Nausea and vomiting are common and distressing side effects of tumor therapy.
Despite prophylaxis, 40–50% of patients suffer from nausea, and 20–30% from vomiting …

Guidelines recommend a combination of a 5-HT 3-receptor antagonist, dexamethasone, and
an NK 1-receptor antagonist in HEC and carboplatin-based chemotherapy. The addition of …

Purpose Radiotherapy-induced nausea and vomiting (RINV) are distressing symptoms.
Evidence-based guidelines should facilitate the prescription of the best possible antiemetic …

To examine pharmacologic and clinical characteristics of neurokinin 1 (NK1)-receptor
antagonists (RAs) for preventing chemotherapy-induced nausea and vomiting (CINV) …

Among the side effects of anticancer treatment, chemotherapy-induced nausea and vomiting
(CINV) is one of the most feared given its high prevalence, affecting up to 40% of patients. It …